BioCentury
ARTICLE | Product Development

Preclinical POC for Codiak’s IL-12 therapy highlight retention benefits of exosomes

November 19, 2020 2:17 AM UTC

Data presented at SITC last week provide preclinical proof of concept for Codiak’s IL-12 therapy and highlight the ability of its exosome-based approach to extend retention in the tumor microenvironment.

Codiak BioSciences Inc. (NASDAQ:CDAK) uses its engEx platform to engineer exosomes to deliver therapeutics that stay localized at the injection site. Lead candidate exoIL-12 displays functional IL-12 on its outer surface and is designed to increase tumor retention and avoid the systemic toxicities that have plagued IL-12 therapies. ...